158 related articles for article (PubMed ID: 27203487)
1. Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
Brusselle G
Lancet; 2016 Apr; 387(10030):1791-2. PubMed ID: 27203487
[No Abstract] [Full Text] [Related]
2. Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
Med Lett Drugs Ther; 2013 Sep; 55(1424):69-71, 45-8. PubMed ID: 26839934
[No Abstract] [Full Text] [Related]
3. vilanterol + fluticasone (RELVAR Ellipta). Asthma and COPD: yet another beta-2 agonist and corticosteroid combination.
Prescrire Int; 2016 Apr; 25(170):94. PubMed ID: 27186620
[TBL] [Abstract][Full Text] [Related]
4. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
[TBL] [Abstract][Full Text] [Related]
5. The lung study promising a breath of fresh air in research world.
Limb M
BMJ; 2015 Nov; 351():h6343. PubMed ID: 26613902
[No Abstract] [Full Text] [Related]
6. Fluticasone-vilanterol combination approved for COPD.
Traynor K
Am J Health Syst Pharm; 2013 Jun; 70(12):1008. PubMed ID: 23719869
[No Abstract] [Full Text] [Related]
7. Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis".
Marshall J; Sharma A; Darken P; Ouwens M; Singh B; Tansey-Dwyer D
Adv Ther; 2023 May; 40(5):2549-2555. PubMed ID: 37004641
[No Abstract] [Full Text] [Related]
8. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
[TBL] [Abstract][Full Text] [Related]
9. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.
Crim C; Calverley PMA; Anderson JA; Holmes AP; Kilbride S; Martinez FJ; Brook RD; Newby DE; Yates JC; Celli BR; Vestbo J;
Respir Med; 2017 Oct; 131():27-34. PubMed ID: 28947039
[TBL] [Abstract][Full Text] [Related]
10. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
Rodrigo GJ; Neffen H
Pulm Pharmacol Ther; 2017 Feb; 42():1-6. PubMed ID: 27864038
[TBL] [Abstract][Full Text] [Related]
11. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
Blair HA; Deeks ED
Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
[TBL] [Abstract][Full Text] [Related]
12. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Bollmeier SG; Prosser TR
Ann Pharmacother; 2014 Feb; 48(2):250-7. PubMed ID: 24259654
[TBL] [Abstract][Full Text] [Related]
13. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?
Groenke L; Disse B
Lancet Respir Med; 2015 Aug; 3(8):e26. PubMed ID: 26282478
[No Abstract] [Full Text] [Related]
14. Umeclidinium bromide and vilanterol in combination for the treatment of chronic obstructive pulmonary disease.
Kelly E
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):403-13. PubMed ID: 24909949
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts.
Brusselle GG; Bracke K; Lahousse L
Lancet Respir Med; 2015 Jun; 3(6):416-7. PubMed ID: 25892351
[No Abstract] [Full Text] [Related]
16. [Not Available].
Steurer J
Praxis (Bern 1994); 2018 Aug; 107(16):918-919. PubMed ID: 30086696
[No Abstract] [Full Text] [Related]
17. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD?--Authors' reply.
Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord I
Lancet Respir Med; 2015 Aug; 3(8):e27. PubMed ID: 26282479
[No Abstract] [Full Text] [Related]
18. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
Woodcock A; Vestbo J; Bakerly ND; New J; Gibson JM; McCorkindale S; Jones R; Collier S; Lay-Flurrie J; Frith L; Jacques L; Fletcher JL; Harvey C; Svedsater H; Leather D;
Lancet; 2017 Nov; 390(10109):2247-2255. PubMed ID: 28903864
[TBL] [Abstract][Full Text] [Related]
19. Triple fixed inhaled therapy in frequent chronic obstructive pulmonary disease exacerbators: potential advantages for various degrees of airways obstruction.
Antohe I; Antoniu SA; Gavrilovici C
Expert Opin Pharmacother; 2018 Feb; 19(3):287-289. PubMed ID: 29271268
[TBL] [Abstract][Full Text] [Related]
20. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
